Literature DB >> 8452359

Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients.

C Lamer1, V de Beco, P Soler, S Calvat, J Y Fagon, M C Dombret, R Farinotti, J Chastre, C Gibert.   

Abstract

Vancomycin penetration into the fluid lining the epithelial surface of the lower respiratory tract was studied by performing fiberoptic bronchoscopy with bronchoalveolar lavage on 14 critically ill, ventilated patients who had received the drug for at least 5 days. The apparent volume of epithelial lining fluid (ELF) recovered by bronchoalveolar lavage was determined by using urea as an endogenous marker. Vancomycin levels in ELF ranged from 0.4 to 8.1 micrograms/ml (mean, 4.5 micrograms/ml), while the mean simultaneous level of the drug in plasma was 24 micrograms/ml (range, 9 to 37.4 micrograms/ml). There was a significant relationship (r = 0.64, P < 0.02) between vancomycin levels in plasma and those in ELF, with a correlation whose slope (0.15) indicated that the blood-to-ELF ratio of drug penetration was 6:1. Using the albumin concentration in ELF as a marker of lung inflammation, we found that vancomycin penetration was higher in patients with ELF albumin values of > or = 3.4 mg/ml than in patients with normal values (< 3.4 mg/ml) (P < 0.02). These results suggest that the vancomycin distribution includes the ELF of the lower respiratory tract at a concentration that is dependent upon the levels in blood and the alveolar capillary membrane protein permeability. These concentrations were well above the MICs for most staphylococci and enterococci.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8452359      PMCID: PMC187653          DOI: 10.1128/AAC.37.2.281

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  Transalveolar transport of large polar solutes (sucrose, inulin, and dextran).

Authors:  J Theodore; E D Robin; R Gaudio; J Acevedo
Journal:  Am J Physiol       Date:  1975-10

2.  Pneumonia in an intensive care unit. A 30-month experience.

Authors:  R M Stevens; D Teres; J J Skillman; D S Feingold
Journal:  Arch Intern Med       Date:  1974-07

3.  APACHE II: a severity of disease classification system.

Authors:  W A Knaus; E A Draper; D P Wagner; J E Zimmerman
Journal:  Crit Care Med       Date:  1985-10       Impact factor: 7.598

4.  Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution.

Authors:  S I Rennard; G Basset; D Lecossier; K M O'Donnell; P Pinkston; P G Martin; R G Crystal
Journal:  J Appl Physiol (1985)       Date:  1986-02

5.  Limitations of using urea to quantify epithelial lining fluid recovered by bronchoalveolar lavage.

Authors:  T W Marcy; W W Merrill; J A Rankin; H Y Reynolds
Journal:  Am Rev Respir Dis       Date:  1987-06

6.  Automated fluorescence polarization immunoassay for monitoring vancomycin.

Authors:  K S Schwenzer; C H Wang; J P Anhalt
Journal:  Ther Drug Monit       Date:  1983       Impact factor: 3.681

7.  Inflammatory and immune processes in the human lung in health and disease: evaluation by bronchoalveolar lavage.

Authors:  G W Hunninghake; J E Gadek; O Kawanami; V J Ferrans; R G Crystal
Journal:  Am J Pathol       Date:  1979-10       Impact factor: 4.307

Review 8.  Bronchoalveolar lavage.

Authors:  H Y Reynolds
Journal:  Am Rev Respir Dis       Date:  1987-01

9.  Fibronectin in human bronchopulmonary lavage fluid. Elevation in patients with interstitial lung disease.

Authors:  S I Rennard; R G Crystal
Journal:  J Clin Invest       Date:  1982-01       Impact factor: 14.808

10.  Prospective evaluation of the protected specimen brush for the diagnosis of pulmonary infections in ventilated patients.

Authors:  J Chastre; F Viau; P Brun; J Pierre; M C Dauge; A Bouchama; A Akesbi; C Gibert
Journal:  Am Rev Respir Dis       Date:  1984-11
View more
  58 in total

1.  Pulmonary disposition of vancomycin in critically ill patients.

Authors:  H Georges; O Leroy; S Alfandari; B Guery; M Roussel-Delvallez; C Dhennain; G Beaucaire
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-05       Impact factor: 3.267

2.  Linezolid in VAP by MRSA: a better choice?

Authors:  Malina Ioanas; Hartmut Lode
Journal:  Intensive Care Med       Date:  2004-02-06       Impact factor: 17.440

3.  Traditional weight-based vancomycin dosing is inadequate in critically ill trauma patients.

Authors:  D D Yeh; M E Kutcher; K Lunghi
Journal:  Eur J Trauma Emerg Surg       Date:  2011-11-15       Impact factor: 3.693

4.  In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus.

Authors:  Mao Hagihara; Dora E Wiskirchen; Joseph L Kuti; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2011-10-17       Impact factor: 5.191

Review 5.  The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections.

Authors:  T Tängdén; V Ramos Martín; T W Felton; E I Nielsen; S Marchand; R J Brüggemann; J B Bulitta; M Bassetti; U Theuretzbacher; B T Tsuji; D W Wareham; L E Friberg; J J De Waele; V H Tam; Jason A Roberts
Journal:  Intensive Care Med       Date:  2017-04-13       Impact factor: 17.440

6.  Should the currently recommended twice-daily dosing still be considered the most appropriate regimen for treating MRSA ventilator-associated pneumonia with vancomycin?

Authors:  Federico Pea; Pierluigi Viale
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 7.  Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infections.

Authors:  Christopher Giuliano; Christopher Giulano; Krystal K Haase; Ronald Hall
Journal:  Expert Rev Anti Infect Ther       Date:  2010-01       Impact factor: 5.091

Review 8.  Treatment strategies for methicillin-resistant Staphylococcus aureus infections in pediatrics.

Authors:  Jason G Newland; Gregory L Kearns
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

Review 9.  Pharmacokinetics and pharmacodynamics of antibacterial agents.

Authors:  Matthew E Levison; Julie H Levison
Journal:  Infect Dis Clin North Am       Date:  2009-12       Impact factor: 5.982

10.  Evaluation of Vancomycin Dosing in Pediatric Cystic Fibrosis Patients.

Authors:  Erin J McDade; Jennifer L Hewlett; Siby P Moonnumakal; Carol J Baker
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Mar-Apr
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.